Literature DB >> 17139806

Management of hypertension in chronic kidney disease.

Pasquale Zamboli, Luca De Nicola, Roberto Minutolo, Valerio Bertino, Fausta Catapano, Giuseppe Conte.   

Abstract

Optimal blood pressure control (<130/80 mm Hg) in patients with chronic kidney disease (CKD), despite being the main objective of conservative therapy, is rarely achieved in clinical practice. A major area of improvement is the correction of the extracellular volume expansion. This goal can be reached by means of dietary salt restriction (100 mEq/d of NaCl). If this intervention fails, hypertension can be treated by thiazide diuretics in patients with mild CKD, whereas loop diuretics at adequate doses are indicated in patients with more advanced CKD. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are more effective than other drugs in slowing progression of proteinuric diabetic and nondiabetic CKD. However, the control rates of blood pressure are usually inadequate with antihypertensive therapy including only these drugs; therefore, addition of other classes of antihypertensive drugs is often required.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17139806     DOI: 10.1007/s11906-006-0029-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  42 in total

1.  Dietary compliance to a low protein and phosphate diet in patients with chronic renal failure.

Authors:  B Cianciaruso; A Capuano; E D'Amaro; N Ferrara; A Nastasi; G Conte; V Bellizzi; V E Andreucci
Journal:  Kidney Int Suppl       Date:  1989-11       Impact factor: 10.545

Review 2.  Does dietary salt increase the risk for progression of kidney disease?

Authors:  Shiraz I Mishra; Charlotte Jones-Burton; Jeffrey C Fink; Jeanine Brown; George L Bakris; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

3.  Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering.

Authors:  Toshio Miyata; Charles van Ypersele de Strihou
Journal:  Nephrol Dial Transplant       Date:  2006-02-13       Impact factor: 5.992

4.  A low-sodium diet potentiates the effects of losartan in type 2 diabetes.

Authors:  Christine A Houlihan; Terri J Allen; Amynta L Baxter; Sianna Panangiotopoulos; David J Casley; Mark E Cooper; George Jerums
Journal:  Diabetes Care       Date:  2002-04       Impact factor: 19.112

Review 5.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

6.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors:  Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

7.  Early changes in bioelectrical estimates of body composition in chronic kidney disease.

Authors:  Vincenzo Bellizzi; Luca Scalfi; Vincenzo Terracciano; Luca De Nicola; Roberto Minutolo; Maurizio Marra; Bruna Guida; Bruno Cianciaruso; Giuseppe Conte; Biagio R Di Iorio
Journal:  J Am Soc Nephrol       Date:  2006-04-12       Impact factor: 10.121

8.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

9.  Role of excess volume in the pathophysiology of hypertension in chronic kidney disease.

Authors:  Nina Vasavada; Rajiv Agarwal
Journal:  Kidney Int       Date:  2003-11       Impact factor: 10.612

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more
  6 in total

1.  Management of intradialytic hypertension: old problem, old drug?

Authors:  Emanuela Rizzioli; Elena Incasa; Susanna Gamberini; Roberto Manfredini
Journal:  Intern Emerg Med       Date:  2009-04-15       Impact factor: 3.397

2.  Hypertension in Cardiovascular and Kidney Disease.

Authors:  Joshua Botdorf; Kunal Chaudhary; Adam Whaley-Connell
Journal:  Cardiorenal Med       Date:  2011-07-30       Impact factor: 2.041

3.  Combination therapy in hypertension: An update.

Authors:  Sanjay Kalra; Bharti Kalra; Navneet Agrawal
Journal:  Diabetol Metab Syndr       Date:  2010-06-24       Impact factor: 3.320

4.  Establishing a renal management clinic in China: initiative, challenges, and opportunities.

Authors:  Ai-Hua Zhang; Hui Zhong; Wen Tang; Shao-Yan Chen; Lian He; Song Wang; Chun Yan Su; Xin-Hong Lu; Tao Wang
Journal:  Int Urol Nephrol       Date:  2008-09-03       Impact factor: 2.370

5.  Resistant hypertension responding to change from furosemide to thiazide: understanding calcium channel blocker-related edema.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-09-07       Impact factor: 3.738

6.  High Intensity Interval Training Favourably Affects Angiotensinogen mRNA Expression and Markers of Cardiorenal Health in a Rat Model of Early-Stage Chronic Kidney Disease.

Authors:  Patrick S Tucker; Aaron T Scanlan; Vincent J Dalbo
Journal:  Biomed Res Int       Date:  2015-05-24       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.